撰文丨王聪 编辑丨王多鱼 排版丨水成文 抗生素耐药性 已成为全球公共卫生的严峻挑战。世界卫生组织 （WHO） 将其列为人类面临的十大公共卫生威胁之一。随着"超 级细菌"的蔓延，传统抗生素正节节败退，寻找具有全新作用机制、细菌难以产生抗药性的候选药物，成为医学界迫在眉睫的挑战。 当传统抗生素逐渐失效，科学家们将目光投向了自然界中存在数百万年、几乎不产生耐药性的 抗菌肽 （A ntimicrobial Peptide， AMP ） 。然而，传统的抗菌肽挖掘方法高度依赖已知多肽的序列相似性，可能错失了大量未被发现的、演化上距离遥远但功能强大的"宝藏"。 | 2026 年 3 月 | 3 日， | 香港中文大学 | 李煜 | 教授 | | --- | --- | --- | --- | --- | | 团队、 | | 中国科学院深圳先进技术研究院 | | | | 戴磊 | 研究员团队合作 | （ | | 余沁 | | 泽 | 、 | 刘红宾 | 、 | | | 施海梅 | 为论文共同第一作者） | | ，在 Nature 子刊 | | | Nature Biomedical Engineering | | 上发表了题 ...

Core Viewpoint - A recent study published in the journal "Frontiers in Microbiology" reveals that an ancient bacterium discovered in a Romanian ice cave exhibits resistance to multiple modern antibiotics, indicating that antibiotic resistance can evolve naturally over time [1][2]. Group 1: Research Findings - The ancient bacterium, named SC65A.3, was found in ice layers formed approximately 5,000 years ago in Romania [1]. - Researchers extracted a 25-meter ice core from the cave and isolated various bacterial strains for genomic sequencing to study their cold resistance mechanisms and antibiotic resistance-related genes [1]. - SC65A.3 showed resistance to 10 out of 28 commonly used clinical or reserve antibiotics, including rifampicin, vancomycin, and ciprofloxacin [1]. - This strain is the first cold-adapted bacterium identified to be resistant to trimethoprim, clindamycin, and metronidazole [1]. - The study identified over a hundred genes associated with antibiotic resistance in SC65A.3, which also has the potential to inhibit the growth of various multidrug-resistant "superbugs" and possesses unique enzymatic activities for biotechnological applications [1]. Group 2: Implications and Concerns - Researchers suggest that strains capable of surviving in cold environments may serve as a "natural reservoir" for antibiotic resistance genes [2]. - The study highlights how antibiotic resistance can evolve in natural environments, predating the use of modern antibiotics [2]. - In light of the increasing global issue of antibiotic resistance, further research on ancient microorganisms like SC65A.3 could provide insights into the natural evolution of antibiotic resistance mechanisms, potentially leading to the development of new drugs and biotechnological products [2]. - There is a warning that climate change could lead to the melting of ice layers, which may release these ancient microorganisms and their resistance genes into modern bacteria, thereby increasing global antibiotic resistance risks [2].

Core Insights - A recent study published in the journal "Frontiers in Microbiology" reveals that an ancient bacterium discovered in a Romanian ice cave exhibits resistance to multiple commonly used antibiotics, indicating that antibiotic resistance can develop through natural evolution [1][2] Group 1: Research Findings - The ancient bacterium was found in ice layers formed approximately 5,000 years ago in Romania [1] - Researchers extracted a 25-meter ice core from the cave and isolated various bacterial strains for genomic sequencing to study their cold resistance mechanisms and antibiotic resistance-related genes [1] - The bacterium named SC65A.3 showed resistance to 10 out of 28 tested antibiotics, including rifampicin, vancomycin, and ciprofloxacin, which are used to treat common infections [1] - SC65A.3 is the first cold-adapted bacterium identified to be resistant to antibiotics such as trimethoprim, clindamycin, and metronidazole [1] - The study found that SC65A.3 carries over a hundred genes related to antibiotic resistance and can inhibit the growth of various multidrug-resistant "superbugs," indicating potential biotechnological applications [1] Group 2: Implications and Future Research - Researchers believe that strains capable of surviving in cold environments may serve as a "natural reservoir" for antibiotic resistance genes [2] - The study highlights how antibiotic resistance can evolve in natural environments, predating the use of modern antibiotics [2] - In light of the increasing global issue of antibiotic resistance, further research on ancient microorganisms may provide insights into the natural evolution of antibiotic resistance mechanisms, potentially leading to the development of new drugs and biotechnological products [2] - There is a warning that climate change could lead to the melting of ice layers, which may release these ancient microorganisms and their resistance genes into modern bacteria, increasing the global risk of antibiotic resistance [2]

Core Insights - The article discusses a recent study published by South China Normal University, highlighting the relationship between environmental exposure and the abundance and transferability of antibiotic resistance genes (ARGs) in the respiratory tract [2][4]. Group 1: Study Findings - Exposure to environmental pollutants is linked to an increase in respiratory antibiotic resistance genes (ARGs) [5]. - The abundance and mobility of antibiotic resistance genes are negatively correlated with lung function [5]. - Enhanced mobility of antibiotic resistance genes is observed in early chronic obstructive pulmonary disease (COPD) [5]. - Environmental pollutant exposure is associated with increased antibiotic-resistant phenotypes in mouse lungs [5]. Group 2: Implications - The study elucidates a pathway through which environmental pollutants contribute to the increase of the respiratory resistance gene pool, indicating the need for action to mitigate the burden of antibiotic resistance by addressing environmental pollution [6].

Core Insights - A new antibiotic, pre-penicillin C lactone, has been discovered during the production process of a commonly used antibiotic, penicillin A, which shows over 100 times higher antibacterial activity against various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus [1][2] Group 1 - The research was conducted by Monash University in collaboration with the University of Warwick, highlighting the potential of intermediate compounds in antibiotic synthesis [1] - The discovery provides a new model for identifying and testing intermediates in the synthesis pathways of various natural compounds, which may lead to the development of new antibiotics to combat antibiotic resistance [1]

Core Insights - A new antibiotic with strong efficacy against "superbugs" has been unexpectedly discovered during the production process of a commonly used antibiotic [1] - The antibiotic, named pre-penicillin C lactone, was found to have over 100 times the antibacterial activity against various Gram-positive bacteria compared to the original antibiotic, penicillin A [1] Group 1: Research Findings - Researchers from Monash University and the University of Warwick identified the antibiotic during the synthesis of penicillin A, which has been known for 50 years but had not been tested for the antibacterial activity of its intermediates [1] - The newly discovered pre-penicillin C lactone is effective against troublesome bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus [1] Group 2: Implications for Antibiotic Development - This discovery provides a new model for finding novel antibiotics by identifying and testing intermediates in the synthesis pathways of various natural compounds [1] - The research highlights the potential for discovering more effective antibiotics to combat antibiotic resistance, a significant issue in modern medicine [1]

Core Insights - A new antibiotic called pre-vancomycin C lactone has been discovered, showing over 100 times higher antibacterial activity against various Gram-positive bacteria compared to the commonly used antibiotic vancomycin A, including resistant strains like MRSA and VRE [1] - The discovery provides a new model for finding novel antibiotics, potentially aiding in the fight against antibiotic resistance [1] Industry Overview - As of November 10, there are 45,700 existing biopharmaceutical companies in China, with 39% located in South China and 32.8% in East China [2] - The registration of biopharmaceutical companies in 2025 has reached 3,311, surpassing the total for 2024, marking a year-on-year increase of 27.3% [3] - In 2025, new registrations are predominantly from East China, accounting for 45.1%, while South China contributes 29.8% [4]

Core Insights - Researchers have discovered a promising new antibiotic, pre-penicillin C lactone, which is effective against "superbugs" resistant to multiple antibiotics, including methicillin-resistant Staphylococcus aureus (MRSA) [1][2] Group 1: Research Findings - The antibiotic pre-penicillin C lactone was found during the production process of the commonly used antibiotic penicillin A, and it exhibits over 100 times higher antibacterial activity against various Gram-positive bacteria compared to penicillin A [1] - This discovery highlights the potential of identifying and testing intermediates in the synthesis pathways of natural compounds to find new antibiotics that can effectively combat antibiotic resistance [1] Group 2: Academic Collaboration - The research was conducted by Monash University in collaboration with the University of Warwick in the UK, indicating a strong international partnership in addressing antibiotic resistance [1]

Core Insights - The World Health Organization (WHO) warns that antibiotic resistance is a growing global health threat, with a significant increase in resistance to commonly used antibiotics [1][2] Group 1: Antibiotic Resistance Statistics - In 2023, one in six laboratory-confirmed bacterial infections globally showed resistance to antibiotic treatment [1] - From 2018 to 2023, over 40% of monitored pathogen-antibiotic combinations exhibited rising antibiotic resistance, with an annual increase of 5% to 15% [1] - More than 40% of Escherichia coli and over 55% of Klebsiella pneumoniae have developed resistance to third-generation cephalosporins, with rates exceeding 70% in the African region [1] Group 2: Regional Variations in Resistance - The WHO reports that the highest risks of antibiotic resistance are in the Southeast Asia and Eastern Mediterranean regions, where one-third of infections show resistance [2] - In the African region, the proportion of infections exhibiting antibiotic resistance is one in five [2] Group 3: WHO's Call to Action - WHO Director-General Tedros Adhanom Ghebreyesus emphasizes the need for responsible antibiotic use and the importance of ensuring access to quality diagnostics and vaccines [2]

Core Insights - An international team led by scientists from the University of Liverpool has developed a new antibiotic named Novltex, which shows sustained inhibitory effects against various deadly superbugs, marking significant progress in the fight against antibiotic resistance [1][2] - Antibiotic resistance is listed as one of the top ten health threats to humanity, causing nearly 5 million deaths annually, with the WHO highlighting the urgent need for new antibiotics [1] - Novltex targets lipid II, a crucial component of bacterial cell walls that is less prone to mutation, offering durable resistance protection against antibiotic resistance [1][2] Summary by Sections Development and Testing - Novltex was inspired by the existing antibiotics Teixobactin and Clofazimine, avoiding the use of expensive raw materials and allowing for the construction of numerous candidate molecules for optimization [2] - The antibiotic demonstrates sustained antibacterial capabilities, remaining effective at low doses and outperforming existing antibiotics like Vancomycin and Daptomycin, with no toxicity to human cells [2] Significance and Potential - The combination of efficiency, durability, and scalability makes Novltex one of the most promising antibiotic candidates in decades [2] - The synthetic efficiency of Novltex is reported to be 30 times higher than that of natural products, enhancing its potential for mass production [2]